CLINICAL_TRIALS
trial_result
· 2020-12-16
Clinical Trial Update: Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) [Phase 2]
Summary
Phase 2 trial update for pembrolizumab monotherapy in metastatic triple-negative breast cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-16